NVO vs VRTX
NVO: A leading global healthcare company focused on conquering chronic diseases, particularly diabetes and cardiovascular conditions. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | NVO | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $47.08 | $477.10 | |
| Market cap as of 2026-08-03 | $223.4B | $121.1B | |
| P/E as of 2026-08-03 | 12.03 | 28.29 | NVO lower |
| PEG as of 2026-08-03 | 16.16 | 2.28 | VRTX lower |
| Net margin as of 2026-08-03 | +37.2% | +35.5% | NVO higher |
| Gross margin as of 2026-08-03 | +81.8% | +86.2% | VRTX higher |
| Operating margin as of 2026-08-03 | +45.3% | +38.3% | NVO higher |
| ROE as of 2026-08-03 | +66.4% | +23.9% | NVO higher |
| ROA as of 2026-08-03 | +23.3% | +17.2% | NVO higher |
| Debt / equity as of 2026-08-03 | 0.72 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.1% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | +20.4% | +10.4% | NVO higher |
| Dividend yield as of 2026-08-03 | +3.8% | n/a | |
| Beta as of 2026-08-03 | 0.89 | 0.48 | |
| 1-year return as of 2026-07-31 close | +0.0% | +4.4% | VRTX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.